Misitatug blivedotin
Based on 1 Customer Validation
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin is formed by conjugating the humanized anti-mesothelin monoclonal antibody Misitatug (HY-P990929) with the microtubule inhibitor Monomethyl auristatin E (MMAE) (HY-15162) via a cleavable linker. Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer.
For research use only. We do not sell to patients.
- Purity : 95.45%
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Misitatug blivedotin (RC88) effectively blocks CA125 from binding to MSLN[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice (female; ages 4–5 weeks; implanted subcutaneously with 3 million OVCAR3‐MSLN‐3# or H292‐MSLN‐9C8 cells for a xenograft model)[3]
-
Dosage:0.7 mg/kg; 0.75 mg/kg; 1.5 mg/kg; 2.1 mg/kg; 3 mg/kg
-
Administration:i.v.; Q1W × 1 or Q1W × 3
-
Result:Had moderate activity at 0.75 mg/kg with single dosing, but tumor volume was less than the initial volume of tumors treated at 2.1 mg/kg until 11 days after dosing.
Significantly reduced the tumors 7 days after the first dosing at 1.5 and 3 mg/kg with multiple dosing.
Fully regressed tumors at 3 mg/kg for 10 days and at 1.5 mg/kg for 17 days, but the tumor continued to grow after three administrations at 0.75 mg/kg.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Misitatug blivedotin]
-
Synonyms
RC88
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Misitatug blivedotin Related Classifications
HY-185561 Related Classifications
Powered by Bioz
Keywords